Sayiner Zeynel Abidin, Munis Hayriye Sultan, Köroğlu İpek, Akyol Elif Melis Baloğlu, Zengin Orhan, Akarsu Ersin
Gaziantep University, School of Medicine, Department of Endocrinology and Metabolism - Gaziantep, Turkey.
Gaziantep University, School of Medicine, Department of Internal Medicine - Gaziantep, Turkey.
Rev Assoc Med Bras (1992). 2024 Dec 2;70(12):e20240871. doi: 10.1590/1806-9282.20240871. eCollection 2024.
Tumor necrosis factor alpha inhibitors are frequently used in the treatment of axial spondyloarthritis. While tumor necrosis factor alpha is associated with some malignancies, studies on its effects on thyroid functions and thyroid nodules are limited. This study aimed to assess the effect of tumor necrosis factor alpha inhibitors treatments on the evaluation of thyroid nodules and thyroid function tests in axial spondyloarthritis patients.
A total of 106 patients with axial spondyloarthritis, 48 receiving nonsteroidal antiinflammatory drugs and 58 receiving tumor necrosis factor alpha inhibitors, were included in the study. All cases were screened by ultrasound for the presence of nodules, European Thyroid Association - Thyroid Imaging Reporting and Data System classification category, thyroid volume, and thyroid function tests.
The prevalence of patients with multiple nodules in the tumor necrosis factor alpha inhibitors treatment group was significantly higher compared to the nonsteroidal antiinflammatory drug group (68.2 vs. 38.1%, p=0.033). Furthermore, the prevalence of nodules measuring ≥1 cm in the tumor necrosis factor alpha inhibitors treatment group was higher compared to the only nonsteroidal antiinflammatory drug treatment group (56 vs. 19.05%, p=0.011). In the tumor necrosis factor alpha inhibitors treatment group, the proportion of patients with nodules requiring fine-needle aspiration cytology was higher compared to the nonsteroidal antiinflammatory drug group (34.5 vs. 16.7%, p=0.038). No significant difference was found between thyroid-stimulating hormone and free thyroxine values before and during treatment in both groups (p>0.005).
The number of nodules requiring fine-needle aspiration cytology according to the European Thyroid Association - Thyroid Imaging Reporting and Data System classification seems higher in nonsteroidal antiinflammatory drugs users than Tumor necrosis factor-alpha inhibitor users. Therefore, it may be rational to examine the thyroid gland while administering Tumor necrosis factor-alpha inhibitor treatment in axial spondyloarthritis patients.
肿瘤坏死因子α抑制剂常用于治疗中轴型脊柱关节炎。虽然肿瘤坏死因子α与某些恶性肿瘤有关,但关于其对甲状腺功能和甲状腺结节影响的研究有限。本研究旨在评估肿瘤坏死因子α抑制剂治疗对中轴型脊柱关节炎患者甲状腺结节评估及甲状腺功能检查的影响。
本研究共纳入106例中轴型脊柱关节炎患者,其中48例接受非甾体类抗炎药治疗,58例接受肿瘤坏死因子α抑制剂治疗。所有病例均通过超声检查甲状腺结节的存在情况、欧洲甲状腺协会-甲状腺影像报告和数据系统分类类别、甲状腺体积以及甲状腺功能检查。
与非甾体类抗炎药组相比,肿瘤坏死因子α抑制剂治疗组多发结节患者的患病率显著更高(68.2%对38.1%,p = 0.033)。此外,肿瘤坏死因子α抑制剂治疗组中直径≥1 cm结节的患病率高于仅接受非甾体类抗炎药治疗组(56%对19.05%,p = 0.011)。在肿瘤坏死因子α抑制剂治疗组中,需要细针穿刺细胞学检查的结节患者比例高于非甾体类抗炎药组(34.5%对16.7%,p = 0.038)。两组治疗前和治疗期间促甲状腺激素和游离甲状腺素值均无显著差异(p>0.005)。
根据欧洲甲状腺协会-甲状腺影像报告和数据系统分类,非甾体类抗炎药使用者中需要细针穿刺细胞学检查的结节数量似乎高于肿瘤坏死因子α抑制剂使用者。因此,在对中轴型脊柱关节炎患者进行肿瘤坏死因子α抑制剂治疗时检查甲状腺可能是合理的。